Sharp divide over plan to curb drug spending

Lawmakers, physicians and patient advocates voiced a wide range of reactions to the Obama administration's proposed drug reimbursement model in a House subcommittee hearing this week, with some arguing the demonstration project should be scrapped entirely and others advocating for slight tweaks to address provider concerns. Patients and providers were equally divided, particularly regarding the impact the program could have on oncology drugs, which are among the specialty drugs expected to increase in costs by 23 percent this year. Read the full article at FierceHealthPayer